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Abstract
Background: In this study, we compared stage at diagnosis, standardized incidence ratio (SIR) and standardized
mortality ratio (SMR) of most frequent cancer diagnoses between re-settlers (Aussiedler) from the former Soviet
Union and the general population in the Saarland in Germany to assess possible delays in diagnosis of cancer
among this migrant group.
Methods: Lung cancer, colorectal cancer, breast cancer, prostate cancer, malignant melanoma of the skin and
stomach cancer diagnoses among a cohort of 18,619 re-settlers living in the Saarland between 1990 and 2009 were
identified by the federal state’s cancer registry. Vital status was available for the respective time-period and used to
calculate SIR and SMR in comparison to the autochthonous population. Tumor stages were condensed into local
and advanced stages. Odds ratios (OR) for an advanced tumor stage were modeled in dependence of re-settler-
status and relevant covariates by logistic regression. Missing values were addressed in a sensitivity analysis. The
influence of duration of stay in Germany on advanced stage diagnosis was analyzed among re-settlers.
Results: SIR and SMR of lung and breast cancer were lower among female re-settlers, while SIR and SMR of
colorectal and prostate cancer were lower among male re-settlers. SIR and SMR of stomach cancer were elevated
among both sexes. Female re-settlers showed an elevated OR for being diagnosed with advanced stage breast
cancer. Both male and female re-settlers showed an elevated OR when observing all six sites combined (OR among
males 1.47, p = 0.04; OR among females 1.37, p = 0.05). The result of elevated ORs was supported in the sensitivity
analysis. Finally, male re-settlers showed a weak association between duration of stay in Germany and reduced risk
for advanced stage diagnosis.
Conclusion: Re-settlers were more likely to be diagnosed at an advanced tumor stage. These findings are in line
with previous research having shown unfavorable health care utilization of re-settlers. Overall, low mortality rates
despite an increased risk of advanced stage at diagnosis argue for a sufficient follow-up care, comparable to the
autochthonous population.
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Background
In 2014, every fifth person living in Germany had a for-
eign background, thereby making Germany a land of im-
migration [1]. Cancer is the second leading cause of
death in Germany [2], and migrant studies are important
to provide insight into early detection and follow-up
care of cancer among these vulnerable populations [3,
4]. To date, there is no study that investigated tumor
stages at time of diagnosis among immigrants in
Germany [3].
A special group within the immigrant population in
Germany are the so-called re-settlers (“Aussiedler” or
“Spätaussiedler” in German), which is the term for eth-
nic Germans from the former Soviet Union (FSU),
whose ancestors had migrated to Russia particularly dur-
ing the 17th and 18th century [5]. With the fall of the
Iron Curtain in 1989 and the dissolution of the Soviet
Union in 1991, more than two million ethnic Germans
immigrated without restrictions by invitation of the Ger-
man government from the FSU to Germany, mainly be-
tween 1990 and 2000 [6, 7]. The FSU states, where the
vast majority of re-settlers originate from, are
Kazakhstan (approx. 50%), the Russian Federation
(approx. 30%) and Kirgizstan (approx. 5%) [8]. All re-
settlers obtained the German citizenship with all rights
and duties directly after migration to Germany [8].
The cancer sites examined in this study are lung can-
cer (LC), colorectal cancer (CRC), breast cancer (BC),
prostate cancer (PC), malignant melanoma of the skin
(MM) and stomach cancer (SC), representing the most
common cancer sites among re-settlers. In our previous
research, we set up a cohort of re-settlers in the federal
state of the Saarland, which is located in the south-west
of Germany at the French border to study cancer inci-
dence. All-cause cancer mortality of the general popula-
tion of the Saarland is relatively high compared to
Germany [9].
PC, BC, LC and CRC are the most common tumors in
the general population of Germany. PC is the most fre-
quent cancer among men in Germany (in 2012 age-
standardized incidence rate (ASIR) 106.7 using European
standard population) and the third most common cancer
related cause of death among men. Similarly, BC is the
most frequent cancer found among women and one out
of eight women is estimated to develop BC during her
lifetime (in 2012 ASIR 117.4) [10]. LC is the second
most common cancer and the most common cause of
death related to cancer in men (in 2012 ASIR 59.1) with
an increasing incidence among women in Germany in
the past decade (in 2012 ASIR 27.7) [10]. CRC is the
second most common cancer in Germany with every
seventh of all cancers diagnosed being either located in
the colon or the rectum (in 2012 ASIR for men 57.0,
ASIR for women 36.5).
In Germany, cancer screening programs for BC, CRC,
PC and MM are being offered systematically for all
members of statutory health insurance (SHI) and private
health insurance (PHI) on a voluntary basis, while
screening for LC is being discussed for cost-effectiveness
[11, 12]. The mammography screening of BC was imple-
mented in the Saarland in 2005, inviting women between
the ages of 50 and 69 every second year. Most BC cases
are diagnosed at an early stage with tumor sizes smaller
than 2 cm accounting for 53% of all diagnoses. Addition-
ally, mammography screening as a method of detection
was shown to be an independent favorable prognostic
factor for overall survival [13]. Considering secondary
prevention of CRC, men and women between 50 and 54
are entitled to an annual fecal occult blood test and from
the age of 55 onwards to a colonoscopy every 10 years.
Following the implementation of screening colonoscopy
in Germany in 2002, age-standardized rates for both in-
cidence and mortality significantly declined within a dec-
ade, contrary to the increasing trend of incidence rates
in the preceding decades. Also, diagnoses of small tu-
mors increased, while tumors with advanced and miss-
ing T status decreased from 2000 to 2008 [14].
Screening for PC entails an annual physical examination
including a digital rectal exam for men above 45 and is
recommended since 1982 [15]. Three quarters of all
diagnoses are early stage diagnoses [12]. Finally, since
the implementation of the skin cancer screening pro-
gram in Germany in 2008, MM incidence in Germany
has more than tripled compared to the 1980s (ASIR 19.2
in both sexes in 2012), while mortality rates remain un-
changed. Two thirds of all diagnoses are early stage diag-
noses [12].
To date, there are no screening methods implemented
into clinical routine for LC and SC. Almost 70% of all
LC patients are diagnosed at stages III or IV [16] and
only 25% of all patients are candidates for surgery at the
time of diagnosis, showing the limited possibilities for ef-
fective treatment at an advanced stage at diagnosis [17].
While the incidence rates for SC have been falling in
Germany and other industrial countries for the last few
decades (ASIR for men 15.6, ASIR for women 8.3 in
2012), overall prognosis of SC is still unfavorable with
relative 5-year survival rates around 30% for both sexes.
Two thirds of all diagnoses are in an advanced stage at
the time of diagnosis.
Stage at diagnosis is an indicator for the time of diag-
nosis and an important determinant for overall progno-
sis. Cancer incidence and mortality show the actual
disease burden and the effectiveness of follow-up ther-
apy. Due to varying risk behavior and health beliefs, mi-
grants often represent a vulnerable subpopulation with
reduced health care access and lower participation in
health care programs, leading to delay in diagnosis [18].
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In this study, we will assess whether tumor diagnoses
among re-settlers are delayed by comparing the tumor
stages at diagnosis between re-settlers and the autoch-
thonous Saarland population utilizing data from the
Saarland cancer registry. The comparison of SIR and
standardized mortality ratios (SMR) will contribute evi-
dence to the evaluation of follow-up care of re-settlers
and whether it is comparable to the general population
in Germany.
Methods
Data and populations
This retrospective, population-based cohort study
observed re-settlers from the FSU who migrated to the
federal state of the Saarland during the period 1990
through 2005. The study cohort was built-up by collect-
ing records of immigrated re-settlers from regional
population registries and finally included 18,619 re-
settlers, which depicts 64% of all re-settlers having
settled in the Saarland in this period [19]. In this manu-
script the terms general population or autochthonous
population of the Saarland describe all inhabitants of
the federal state excluding the population of our cohort.
The representativeness of the cohort for this period has
been ensured in previous studies as cardio-vascular dis-
ease mortality is similar in a large representative cohort
of re-settlers in the state of Northrhine-Westphalia
[19]. Vital status and causes of death of re-settlers was
Germany-wide ascertained through local population
and health registries between 1990 and 2009 for 95% of
the cohort [20].
The Saarland Cancer Registry provided information on
incident cases of LC (ICD-9: 162), CRC (ICD-9: 153,
154), BC (ICD-9: 174), PC (ICD-9: 185), MM (ICD-9:
172) and SC (ICD-9: 151) from 1990 to 2009. All cancer
diagnoses occurring after an initial cancer diagnosis were
considered multiple primary tumors. Multiple primary
tumors were included in all analyses. The Saarland
Cancer Registry was established in 1967 and covers the
population of the federal state with its approximately
1.02 million inhabitants by the end of 2009 [21]. The co-
hort was set up in the Saarland because of high data
quality of the state’s cancer registry.
Information on International Classification of Diseases
9 (ICD-9) code, sex, age at diagnosis, region of residence
and TNM classification were available. A variable ‘popu-
lation density of region of residence’ was created by
categorizing each of the seven districts of the Saarland
into three categories of population density (less than 300
inhabitants per km2 [inh./km2], 300 inh./km2 to 700
inh./km2 and more than 700 inh./km2). We introduced
the variable to be able to control for rural-urban differ-
ences which we assumed to influence access to health
services, as access might be poorer in rural areas [22].
Computer assisted record linkage was used to identify
re-settlers within local population registries and the can-
cer registry data via name and date of birth [19].
For the analysis of cancer registry data, the European
Network of Cancer Registries (ENCR) recommends a
condensed coding of stages [23] due to expected missing
values in population-wide data and varying versions of
the TNM classification. For this reason, N and M status
were used to categorize stages into a local (N0 M0 or
N0 Mx), advanced (N +M+ or N +Mx or NxM+) or
missing stage (NxM0 or NxMx) for all studied cancer
sites. The definition of condensed stages and stage distri-
bution is shown in Table 1.
Statistical methods
Person-years (PY) were calculated for each sex, five-year
age group, and calendar year. SMR for each cancer site
was calculated using recorded deaths and PY of re-
settlers together with age-specific death rates of the
Saarland population. For SIR analysis, re-settlers were
censored when moving out of the Saarland and PY were
calculated for living within the Saarland accordingly. In-
cident cancer diagnoses among re-settlers, PY within the
Saarland and age-specific incidence rates of the Saarland
population were used to calculate SIR. SIR was calcu-
lated for each tumor type separately and for all sites
combined. Ninety-five percent confidence limits (95%CI)
were calculated using the exact method [24].
Logistic regression was performed to assess the associ-
ation between advanced stage at diagnosis and re-settler
status. Condensed stage (advanced-local) at diagnosis
was the dependent, and re-settler status the independent
variable while adjusting for age at diagnosis, year of
diagnosis and population density of region of residence.
The model was calculated separately for each sex and
cancer site as well as for all sites combined including all
LC, CRC, BC, PC, MM and SC diagnoses from the Saar-
land cancer registry between 1990 and 2009. Male MM
cases were not analyzed individually, as there were no
advanced stage diagnoses registered among re-settlers,
but they were included in the combined analysis.
A sensitivity analysis including all studied cancer sites
was performed to assess the influence of cases with
missing information on staging, in which two possible
scenarios were considered. In the best-case scenario, all
cases with missing stage were considered as local stage
and in the worst-case scenario as advanced stage.
An additional logistic regression was performed
among re-settlers only to assess the influence of dur-
ation of stay in Germany on the diagnosis of advanced
stages. As we assumed a non-linear trend, condensed
stage at diagnosis was modeled conditional to duration
of stay in Germany, transformed as a quadratic term.
Transformation was determined using fractional
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Table 1 Description and distribution of condensed staging
Stage T status N status M status Cancer site Re-settlers N (%) General population N (%)
Local Any – – Lung cancer 5 (5.3%) 1221 (7.8%)
Colorectal cancer 9 (11.5%) 3059 (16.1%)
Breast cancer 31 (33.7%) 5512 (35.0%)
Prostate cancer 4 (7.5%) 1357 (11.0%)
Malignant melanoma 12 (57.1%) 1514 (53.9%)
Stomach cancer 11 (16.9%) 367 (7.5%)
All sites combined 72 (17.9%) 13,030 (18.5%)
Any – Missing Lung cancer 1 (1.1%) 436 (2.8%)
Colorectal cancer 17 (21.8%) 3505 (18.5%)
Breast cancer 4 (4.3%) 883 (5.6%)
Prostate cancer 14 (26.4%) 2069 (16.7%)
Malignant melanoma 1 (4.8%) 39 (1.4%)
Stomach cancer 3 (4.6%) 358 (7.3%)
All sites combined 40 (9.9%) 7290 (10.4%)
Advanced Any + – Lung cancer 22 (23.4%) 2272 (14.6%)
Colorectal cancer 9 (11.5%) 1862 (9.8%)
Breast cancer 30 (32.6%) 3579 (22.7%)
Prostate cancer 0 (0.0%) 110 (0.9%)
Malignant melanoma 1 (4.8%) 107 (3.8%)
Stomach cancer 8 (12.3%) 462 (9.4%)
All sites combined 70 (17.4%) 8392 (11.9%)
Any + Missing Lung cancer 7 (7.4%) 715 (4.6%)
Colorectal cancer 15 (19.2%) 2555 (13.5%)
Breast cancer 9 (9.8%) 1352 (8.6%)
Prostate cancer 0 (0.0%) 261 (21.1%)
Malignant melanoma 0 (0.0%) 29 (1.0%)
Stomach cancer 7 (10.8%) 622 (12.6%)
All sites combined 38 (9.4%) 5534 (7.9%)
Any Any + Lung cancer 33 (35.1%) 5393 (34.6%)
Colorectal cancer 15 (19.2%) 2861 (15.1%)
Breast cancer 8 (8.7%) 1115 (7.1%)
Prostate cancer 1 (1.9%) 605 (4.9%)
Malignant melanoma 2 (9.5%) 156 (5.6%)
Stomach cancer 14 (21.5%) 988 (20.1%)
All sites combined 73 (18.1%) 11,118 (15.8%)
Missing Any Missing – Lung cancer 1 (1.1%) 322 (2.1%)
Colorectal cancer 0 (0.0%) 226 (1.2%)
Breast cancer 0 (0.0%) 312 (2.0%)
Prostate cancer 0 (0.0%) 572 (4.6%)
Malignant melanoma 2 (9.5%) 134 (4.8%)
Stomach cancer 0 (0.0%) 60 (1.2%)
All sites combined 3 (0.7%) 1626 (2.3%)
Any Missing Missing Lung cancer 25 (26.6%) 5206 (33.4%)
Colorectal cancer 13 (16.7%) 4879 (25.8%)
Breast cancer 10 (10.9%) 2989 (19.0%)
Prostate cancer 34 (64.2%) 7400 (59.8%)
Malignant melanoma 3 (14.3%) 830 (29.5%)
Stomach cancer 22 (33.8%) 2063 (41.9%)
All sites combined 107 (26.6%) 23,367 (33.2%)
(−: not involved, +: involved)
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polynomials [25]. The analysis was adjusted for age at
diagnosis, year of diagnosis and population density of re-
gion of residence. We calculated this model separately
for each sex and for the six cancer sites combined.
The statistical software R was used to conduct statis-
tical analyses (Version 3.13).
Results
The Saarland Cancer Registry observed 15,565 diagnoses
of lung cancer, 18,947 diagnoses of colorectal cancer,
15,742 diagnoses of female breast cancer, 12,374 diagno-
ses of prostate cancer, 2809 diagnoses of malignant mel-
anoma and 4920 diagnoses of stomach cancer in the
Saarland between 1990 and 2009. Among the re-settler
cohort 94, 78, 92, 53, 21 and 65 diagnoses were ob-
served, respectively.
A descriptive analysis of the re-settler cohort including
their accumulated PY used to calculate SIR and SMR is
shown in Table 2. Concerning LC, male re-settlers’ SIR
and SMR was somewhat higher than the general popula-
tion of the Saarland however not significantly, while
female re-settlers had significantly lower SIR and SMR of
LC (Table 3, SIR = 0.42 95%CI 0.21–0.76, SMR = 0.53
95%CI 0.29–0.89). Male re-settlers had lower SIR and
SMR of CRC (SIR = 0.50 95%CI 0.34–0.72, SMR = 0.52
95%CI 0.30–0.85), while female re-settlers had comparable
SIR and SMR. Female re-settlers had lower SIR and SMR
of BC (SIR = 0.80 95%CI 0.65–0.98, SMR = 0.63 95%CI
0.42–0.93), while male re-settlers had lower SIR and SMR
of PC (SIR = 0.75 95%CI 0.57–0.98, SMR= 0.30 95%CI
0.11–0.65). Both male and female re-settlers had
comparable SIR and SMR of MM. Considering SC, both
male and female re-settlers had higher SIR and SMR (SIR
for males = 2.22 95%CI 1.55–3.07, SMR for males = 1.91
95%CI 1.25–2.81, SIR for females = 2.32 95%CI 1.56–3.35,
SMR for females = 2.15 95%CI 1.38–3.18). Finally, for all
cancer sites combined, male re-settlers had comparable
SIR and SMR and female re-settlers had somewhat lower
SIR and SMR however not significantly. Additionally,
SMR was comparable to SIR in all cases.
Results of the logistic regression of condensed staging
are shown in Table 4. Both male and female re-settlers
were more likely to be diagnosed at an advanced con-
densed stage than the general population, yielding an
adjusted odds ratio (OR) of 1.47 (95%CI 1.02–2.10) for
males and 1.37 (95%CI 1.00–1.89) for females when
analyzing all six sites combined. Male re-settlers had ele-
vated ORs for advanced stage diagnosis of LC and CRC,
although not significantly. Female re-settlers showed a
higher percentage distribution of advanced stage at
diagnosis of BC with an adjusted OR of 1.60 (95%CI
1.03–2.48) and of MM with an adjusted OR of 4.29
(95%CI 0.99–18.60). Female re-settlers also had
increased ORs in LC and CRC cases. Re-settlers had a
reduced OR of advanced stage diagnosis of SC and PC
cases, however not significantly. In the sensitivity ana-
lysis, re-settler status was associated with an advanced
stage at diagnosis for both sexes in the best-case sce-
nario with adjusted ORs of 1.32 (95%CI 1.00–1.75) for
male and 1.44 (95%CI 1.08–1.91) for female re-settlers.
Re-settlers also presented elevated ORs in the worst-case
scenario, however not significantly. Re-settlers had sig-
nificantly less missing data on condensed staging than
the general population (p < 0.01).
There was a quadratic association (p = 0.10) between the
duration of stay (years) in Germany and a reduced risk of
an advanced stage at diagnosis in male re-settlers (Table 5).
For female re-settlers, no association was found.
Discussion
Both male and female re-settlers were more likely to be
diagnosed at an advanced stage compared to the general
population in the Saarland, as seen for all studied cancer
sites combined among both sexes and female BC cases.
However, they had lower or comparable cancer inci-
dence and mortality rates of all studied cancer sites
except SC. In general, cancer incidence and mortality
reflected rates in their country of origin [26]. Addition-
ally, there was a weak association of duration of stay in
Germany and reduced risk of advanced stage at diagno-
sis among male re-settlers, while no association was
found among female re-settlers.
The main strength of this study was its representative-
ness with an observation period of 20 years and its
inclusion of a large number of re-settlers who are
Table 2 Descriptive results of the re-settler cohort for the
follow-up period 1990–2009
Number of cohort members 18,619
Male 8976 (48.2%)
Female 9643 (51.8%)
Immigration period 1990–2005
1990–1993 6933
1994–1997 6536
1998–2005 5150
End of follow-up
Alive 16,391 (88.0%)
Dead 1314 (7.1%)
Cause of death known 1204 (91.6%)
Lost to follow up 914 (4.9%)
Incidence
(inside Saarland)
Mortality
(Germany-wide)
Person-years 204,366.3 243,369.1
Males 98,622.6 117,310.7
Females 105,743.7 126,059.1
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generally hard to identify in population health research
[19]. Additionally, the Saarland Cancer Registry provides
a high completeness of cover of about 95%, as cancer
registration is mandatory by law [27]. In addition, there
have not been any studies about the stage at diagnosis of
cancers among migrant subpopulations in Germany
before [3].
One restriction of this study was its incomplete dis-
tinction of re-settlers and non-re-settlers. Since the
study cohort covered only 64% of all re-settlers living in
the Saarland, incidence data of the general population of
the Saarland included a small number of re-settler cases.
A complete distinction between re-settlers and the gen-
eral population would have resulted in clearer results.
However, results were biased towards the null, which
makes us confident of having avoided overestimation in
our results.
Numbers of deaths among the re-settler cohort are
based on a Germany-wide follow up, which were com-
pared to the mortality rates of the general population in
the Saarland in SMR analysis. For most of the follow-up
period, the general population of the Saarland had
higher male LC mortality rates than the average rate in
Germany [19]. In a previous publication on re-settlers,
SIR analysis excluded multiple primary tumor diagnoses
and the general German population was used as the ref-
erence population in SMR analysis [19, 28], accounting
for lower SIR and SMR in the present analysis.
In order to unify data that is based on changing ver-
sions of the TNM classification over a period of 20 years,
data on lymph node involvement (N) and distant metas-
tasis (M) according to the Union for Cancer Control
(UICC) was used to determine a condensed staging sys-
tem as proposed by the European Network of Cancer
Registries [23]. N0 Mx was defined as local stage, since
96.5% of all complete cases with a N0 diagnoses in the
dataset were local stage (N0 M0) diagnoses. When defin-
ing N0 Mx as missing, we obtained similar ORs as
shown in Table 4 for all cancer sites combined (OR for
men 1.48, 95% CI 0.98–2.23; OR for women 1.43, 95%
CI 1.00–2.04), showing that a misclassification bias is
unlikely using this classification.
In the sensitivity analysis, re-settlers had elevated ORs
in both the best-case and the worst-case scenario, while
not significant on a level of α = 5% in the worst-case
scenario. This is attributable to the significantly lower
proportion of missing data in the staging variable of re-
settlers compared to the general population (p < 0.01).
Table 3 Standardized incidence ratios and standardized mortality ratios
Tumor type Males Females
(ICD-10) Observed SIR SMR Observed SIR SMR
Incidence Mortality (95% CI) (95% CI) Incidence Mortality (95% CI) (95% CI)
Lung (C33–34) 83 87 1.16 (0.94–1.44) 1.09 (0.89–1.35) 11 14 0.42 (0.21–0.76) 0.53 (0.29–0.89)
Colorectal (C17–21) 29 16 0.50 (0.34–0.72) 0.52 (0.30–0.85) 49 27 0.92 (0.68–1.22) 0.91 (0.60–1.33)
Breast (C50) 92 27 0.80 (0.65–0.98) 0.63 (0.42–0.93)
Prostate (C61) 53 6 0.75 (0.57–0.98) 0.30 (0.11–0.65)
Malignant melanoma (C43) 9 2 0.89 (0.41–1.69) 0.73 (0.09–2.64) 12 2 1.00 (0.52–1.76) 0.86 (0.10–3.11)
Stomach (C16) 36 26 2.22 (1.55–3.07) 1.91 (1.25–2.81) 29 24 2.32 (1.56–3.35) 2.15 (1.38–3.18)
Table 4 Logistic regression of advanced stage diagnosis in dependence of re-settler status, adjusted for possible confounders
Tumor type Males Females
Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
Lung cancer 2.05 (0.82–5.12) 0.13 1.48 (0.18–12.12) 0.71
Colorectal cancer 1.47 (0.64–3.53) 0.37 1.24 (0.66–2.31) 0.50
Breast cancer 1.60 (1.03–2.48) 0.04
Prostate cancer 0.24 (0.03–1.84) 0.17
Malignant melanoma of the skin NAa NAa 4.29 (0.99–18.60) 0.05
Stomach cancer 0.77 (0.29–2.04) 0.60 0.54 (0.21–1.39) 0.20
All sites combined 1.47 (1.02–2.10) 0.04 1.37 (1.00–1.89) 0.05
Sensitivity analysis
Best case scenario (all missings as local) 1.32 (1.00–1.75) 0.05 1.44 (1.08–1.91) 0.01
Worst case scenario (all missings as advanced) 1.32 (0.95–1.84) 0.09 1.22 (0.90–1.65) 0.20
anot applicable due to low number of cases
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Female re-settlers had less death certificate only (DCO)
cases than the general population (p = 0.04), while DCO
distribution was comparable among male re-settlers.
Additionally, the confidence interval marginally included
1.00 in both sexes in the worst-case scenario.
Significant greater completeness of data among re-
settlers suggests differences in the process of diagnoses
between re-settlers and non-re-settlers. It is difficult to
predict whether the missing data in the staging variable
is more likely to be local or advanced. However, we are
confident that the results of the sensitivity analysis sup-
port our findings of an increased risk of advanced stage
diagnoses among re-settlers despite missing data.
Population density of region of residence was used to
adjust for assumed rural-urban differences in access to
health care. We hypothesized that people living in rural
areas might have worse access to health care and thus
might present more advanced stages at diagnosis than
people living in urban areas [22, 29]. Also, the age and
the year of diagnosis were considered possible con-
founders for the analysis of stage at diagnosis.
Somewhat higher incidence and mortality from LC
among male re-settlers can be best explained with
tobacco smoking. An analysis of micro census data sup-
ports this conclusion by having shown that especially
male re-settlers import health-related risks such as a
high smoking prevalence from their countries of origin
(Kazakhstan, Russia, Kirgizstan), while prevalence con-
verges with increasing length of stay to the prevalence of
the country of destination [30]. The finding of a lower
LC incidence among female re-settlers is in line with
studies having demonstrated a lower smoking prevalence
in this population [30]. Current and previous smokers
are more likely to be diagnosed with advanced stage LC
than never-smokers, which could have contributed to
our finding of an insignificantly higher proportion of
advanced stages among male re-settlers with LC [31].
Additionally, early symptoms of LC are very unspecific,
emphasizing the importance of an early involvement of
specialists in the diagnostic process of suspected LC
patients [16]. Recent analyses show that re-settlers may
be less likely to visit specialists [32, 33], which thus
might contribute to a possible delay in LC diagnosis
among re-settlers.
Lower BC incidence and mortality of female re-
settlers reflect rates in the Russian Federation [26].
This may be due to parallels of reproductive factors
in their countries of origin. Early parity is a protective
factor for BC [34] and women in the Russian Feder-
ation are on average 4–5 years younger at their first
birth than women in Germany [26, 35]. Furthermore,
advanced stage is associated with patient delay of
diagnosis and non-participation in general health
screening examinations for BC in the general popula-
tion of the Saarland, suggesting a need for better
inclusion of female re-settlers into the German
healthcare system [36]. However, BC screening was
introduced only in 2005. With an observation period
of our cohort from 1990 to 2009, we assume that the
influence of screening on cancer stages in our cohort
was probably small. Additionally, a lower mortality
despite more advanced stages argues for an efficient
follow-up care.
Elevated risks of stomach cancer and reduced risks of
colorectal and prostate cancer are in line with previous
findings of increased risks of cancers related to infec-
tions in early life (e. g. stomach cancer) and reduced
risks of cancers related to a western lifestyle (e. g. colo-
rectal cancer, prostate cancer) among re-settlers. The
differences of mortality also reflect rates in the Russian
Federation [26]. These differences may be due to various
risk factors including lifestyle, diet and Helicobacter
pylori infection [37].
The comparison of the Gleason score may have been
more informative than the comparison of condensed
stages in the case of PC [38], however, this data was not
available to us. A large proportion of cases with missing
data on staging particularly among PC and to a smaller
degree also among SC cases makes it difficult to conclude
on differences of those entities between re-settlers and the
general population. Concerning SC, cases were frequently
detected at a final stage also in the general population of
the Saarland, which decreased the difference to re-settlers.
CRC screening has been introduced in Germany in
2002, thus, re-settlers have had access to regular colon-
oscopy examination during the last 8 years of observa-
tion. As stage at diagnosis was not more advanced
among re-settlers, we could not find strong evidence for
major differences in the diagnostic process. However,
more research is needed to draw a final conclusion on
possible delays in the diagnosis of CRC.
Interestingly, there was a distinct disparity in the dis-
tribution of stages between male and female re-settlers
Table 5 Association between duration of stay in Germany and
advanced stage diagnosis in re-settlers
Males Females
Coefficients Odds ratio p-value Odds ratio p-value
Duration of stay (years2) 0.995 0.10 1.002 0.37
Age at diagnosis (years) 0.963 0.04 0.996 0.77
Year of diagnosisa 1.113 0.07 0.894 0.02
Population density of region
of residence [inhabitants/km2]
0.26 0.75
< 300 (ref.)
300–700 0.169 0.734
> 700 0.173 0.705
acoded as calendaryear-1990
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with MM. While female re-settlers showed a more
balanced distribution of stages and an elevated risk for
an advanced stage at diagnosis compared to the autoch-
thonous population, male re-settlers presented no
advanced stage diagnoses and 8 local stage diagnoses.
Due to this imbalanced distribution, logistic regression
could not be carried out for male MM cases. Further-
more, MM screening could not have played a significant
role in the diagnostic process as it was introduced only
at the end of the observation period. Ultimately, no clear
conclusion can be drawn due to the small sample size
for MM. Considering our finding of later stages of MM
cases among female re-settlers, we propose to explore
differences in MM screening behavior between the sexes
in the future. Overall, SMR and SIR of re-settlers were
comparable and SMR was never significantly elevated
except for SC. Those results argue for an efficient treat-
ment, comparable to the autochthonous population.
Future survival studies investigating re-settlers should
adjust for tumor stage at diagnosis.
Comparable mortality rates despite an overall elevated
risk of advanced stage at diagnosis may be attributable to
several factors besides the diagnostic process. Different
histologic subtypes may play a role, as it has been shown
in the case of SC, where re-settlers show a higher propor-
tion of prognostic favorable histologic types compared to
the general population of the Saarland [37]. In addition,
specific cancer characteristics such as speed of growth
could lead to more advanced stages in this group.
Our results finally support previous findings on health
care utilization of re-settlers. Findings from the KORA
survey in 2000 showed that re-settlers are less likely to
participate in cancer prevention programs and that they
indicate more often being less informed about the health
care system in Germany [32]. Also, they were more
likely to seek medical advice from the lay referral system
(seeking for medical advice online or from family and
friends), rather than visiting a specialist physician [39].
Our finding of more advanced stages of several cancer
sites with different etiologies among re-settlers is sup-
porting the conclusion that a delay in the diagnostic
process rather than the dominance of faster growing
cancer entities is a likely explanation for more advanced
stages of re-settlers.
All re-settlers obtained the German citizenship with
migration to Germany which gave them direct access to
German social security systems including health insur-
ance [8]. In general, the ratio of people without access to
health coverage is low in Germany. In the year 2007,
2 years before the introduction of mandatory health
insurance in 2009, the number of inhabitants without
health insurance peaked with 400,000 (0.5%) [40]. In
addition, socio-economic position of re-settlers is mod-
erate, being in-between autochthonous Germans and
other migrants in Germany [8]. In conclusion, health
care utilization rather than health coverage is a plausible
explanation for their more advanced stages.
Last, there was a weak association of duration of stay
in Germany with the risk of advanced stage at diagnosis
of male re-settlers, but not of female re-settlers. With
longer duration of stay, the risk for later cancer diagno-
sis among male re-settlers seems to decrease slowly.
Possible reasons include slightly ameliorating integration
into the German healthcare system, a change in risk
factor exposure or health care utilization [24, 28, 41].
Conclusion
In conclusion, re-settlers were more likely to be diag-
nosed at an advanced tumor stage. Findings are most
likely due to high proportions of advanced stages of LC
cases among males and BC and MM cases among
females, while re-settlers presented a comparable pro-
portion of stages at diagnosis of CRC, SC and PC cases.
Thus, the tendency to rarely visit specialists and to
participate in prevention programs less frequently may
lead to a delay in diagnosis. Overall, comparable mortal-
ity rates despite an increased risk of advanced stage at
diagnosis argue for an efficient follow-up care compar-
able to the autochthonous population. Future studies
should focus on determining specific risk factors for a
delay in diagnosis of cancer and attainable preventive
methods to promote early diagnosis in a specialist
setting for this group of migrants.
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